- Conditions
- Cognition Disorder, Attention Deficit Disorder, Traumatic Brain Injury
- Interventions
- Methylphenidate
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Cancer-related Cognitive Dysfunction
- Interventions
- Accelerometry, Aerobic Exercise, Electronic Health Record Review, Functional Magnetic Resonance Imaging, Gait Assessment Test, Health Education, Interview, Neurocognitive Assessment, Physical Performance Testing, Questionnaire Administration
- Procedure · Other · Behavioral
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- Meta-Cognitive Therapy, Supportive Therapy
- Behavioral
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Neuro-typical controls and ADHD will receive EVO game play.
- Device
- Lead sponsor
- Akili Interactive Labs, Inc.
- Industry
- Eligibility
- 8 Years to 12 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Bradenton, Florida • Durham, North Carolina
- Conditions
- Cancer-related Problem/Condition, Cognitive Impairment
- Interventions
- MAAT-G
- Behavioral
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Antisocial Behavior
- Interventions
- Attention to Context (ATC) training, Affective Cognitive Control (ACC) training
- Behavioral
- Lead sponsor
- The Mind Research Network
- Other
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Huntington Disease, Chorea
- Interventions
- atomoxetine, Matching Placebo
- Drug
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Bipolar Disorder, Cognitive Impairment
- Interventions
- Quetiapine XR, Placebo
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Durham, North Carolina
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Methylphenidate, Placebo
- Drug · Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 8 Years to 12 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Breast Cancer Survivors
- Interventions
- Not listed
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 50 Years to 70 Years · Female only
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Lisdexamfetamine
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 12 Years to 30 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- galantamine
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- Cognitive behavioral therapy, Drug therapy
- Behavioral · Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Symptomatic Menopause, Cognitive Impairments
- Interventions
- Lisdexamfetamine, Placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 45 Years to 60 Years · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Sickle Cell Disease, Cognitive Impairment
- Interventions
- Cogmed
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 8 Years to 16 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Brain Concussion, Brain Trauma, Attention Concentration Difficulty, Brain Injuries, Brain Injuries, Traumatic, Neurocognitive Dysfunction, Attention Impaired, Memory Impairment, Mild Traumatic Brain Injury, Mild Cognitive Impairment, Post Concussive Symptoms
- Interventions
- Active tDCS and Cognitive Training Intervention, Sham tDCS and Cognitive Training Intervention
- Combination Product
- Lead sponsor
- United States Naval Medical Center, San Diego
- Federal
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 2
- States / cities
- San Diego, California • Minneapolis, Minnesota
- Conditions
- Traumatic Brain Injury
- Interventions
- BrainHQ, Goal Management Training
- Behavioral
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 21 Years to 55 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Modafinil
- Drug
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy
- Interventions
- Scopolamine + Donepezil Placebo + PF-04995274 Placebo, Scopolamine + Donepezil 5 mg + PF-04995274 Placebo, Scopolamine + Donepezil 10mg + PF-04995274 Placebo, Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg, Scopolamine + Donepezil Placebo + PF-04995274 15 mg
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Aging, MCI
- Interventions
- MediTrain, Worder, noninvasive neurostimulation device, wrist worn multi-sensor watches
- Device
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Traumatic Brain Injury, Mild Traumatic Brain Injury, Aging, Cognitive Decline
- Interventions
- Alpha neurofeedback training, Visual Attention Training
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Huntington Disease, Chorea, Executive Dysfunction
- Interventions
- 20mg daily citalopram, Placebo
- Drug
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Iowa City, Iowa • Rochester, New York
- Conditions
- Aging, MCI, Cognitive Decline
- Interventions
- MediTrain, Worder
- Device
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 60 Years to 99 Years
- Enrollment
- 4,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD)
- Interventions
- L-theanine and paraxanthine, Placebo
- Dietary Supplement
- Lead sponsor
- Texas Tech University Health Sciences Center
- Other
- Eligibility
- Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Lubbock, Texas